 |
|
|
| |
Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection
|
| |
| |
AASLD 2020 Nov 11-16
MF Yuen1, E Berliba2, YJ Kim3, J Holmes4, Y-S Lim5, S Strasser6, C Schwabe7, A Jucov2, ACH Lee8, EP Thi8, T Harasym8, GR Pamulapati8, P Wattamwar8, J Kunta8, M Sofia8, HSevinsky9, K Gray9, T Eley9,G Picchio9, KD Sims9, E Gane7
|
| |
|
|
|
|
|
